Kerrie Brady

Kerrie Brady is a seasoned biotechnology entrepreneur with a proven track record of leading successful ventures in the biotech industry. With deep expertise in fundraising, licensing strategies, and corporate development, Kerrie has steered multiple emerging biotech companies through pivotal growth stages. A strategic leader, Kerrie has secured over $230 million in investments from venture capital and private investors, leveraging extensive connections with life science banking and institutional investors. 

Renowned for negotiating high-impact deals, Kerrie led the $1B out-licensing deal with Eli Lilly, marking the largest-ever Phase 1 asset agreement in the pain management sector. Her background in both science and business, with a degree in Pharmacy, an MBA and a Master's in Biopharmaceuticals, allows Kerrie to build trust and credibility across diverse stakeholders, including scientists, investors, and industry leaders.

As a thought leader and mentor, Kerrie has contributed to the biotech community by serving on boards, including Neurocentrx Pharm Therapeutics, where she is Chairperson, Invea Therapeutics where she chairs the Audit Committee,  and Asklepion Pharmaceuticals. An early adopter of AI-driven drug development, Kerrie also holds a certification in AI and Machine Learning from MIT and actively mentors the next generation of biotech leaders.